Novartis (NYSE:NVS) division Sandoz said today that it launched its Symjepi epinephrine pre-filled syringe in the U.S.
The company’s product is designed as an alternative to epinephrine auto-injectors to treat emergency allergic reactions.
Sandoz described Symjepi as an “affordable” alternative to EpiPens but did not disclose the product’s price.
“The Symjepi device is small in size and fits into the palm of your hand, with the goal of a simple-to-use application and intuitive, user-friendly design,” Sandoz president Carol Lynch said in prepared remarks.
“At Sandoz, we strive to reimagine medicine to offer the best care we can in all we do, and having heard from patients, caregivers and healthcare professionals about their eagerness for a new product, we are proud to be a part of the solution to a critical need in the U.S.,” Lynch added.
Last year, a number of epinephrine auto-injector manufacturers reported supply issues to the FDA.
